Untitled

Mall, Julian W.; Philipp, Andreas; Mall, W; Pollmann, Christian

doi:10.1023/a:1021546630577

Cited by 7 publications

(2 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…underlining the possible role of angiogenesis inhibitors in combination with traditional chemotherapy in the SCLC(35). A phase II trial evaluated thalidomide as maintenance therapy in 30 patients with ES-SCLC who had received first-line chemotherapy without progression disease(36).…”

mentioning

confidence: 99%

Angiogenesis Inhibitors in Small Cell Lung Cancer

et al. 2021

View full text Add to dashboard Cite

Inhibition of angiogenesis has been demonstrated to be an efficacious strategy in treating several tumors. Vascular endothelial growth factor (VEGF) is the most important protein with proangiogenic functions and it is overexpressed in small cell lung cancer (SCLC). Bevacizumab, a monoclonal antibody directed against VEGF, showed a promising activity in combination with etoposide and cisplatin as first-line treatment of patients with extended stage (ES)-SCLC and two randomized studies confirmed that bevacizumab improved PFS, but failed to prolong OS. Instead, disappointing results have been observed with endostar, sunitinib, sorafenib, vandetanib, and thalidomide in combination with chemotherapy in the first-line setting, with sunitinib in the maintenance setting, with sunitinib, cediranib and nintedanib as single agents or ziv-aflibercept in combination with topotecan in second-line setting. Only anlotinib improved OS and PFS as third-line therapy in Chinese patients with SCLC, and it was approved with this indication in China. Future challenges are the evaluation of the role of angiogenesis inhibitors in combination with immune- checkpoint inhibitors and chemotherapy in SCLC patients and the identification of predictive biomarkers of response to both agents.

show abstract

mentioning

confidence: 99%

Angiogenesis Inhibitors in Small Cell Lung Cancer

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Mall et al reported a long-term survival in an SCLC patient after administration of thalidomide and combination chemotherapy 22. A phase II study assessing thalidomide as maintenance therapy in extensive-stage SCLC after response to chemotherapy showed that thalidomide has acceptable side effects 23.…”

Section: Thalidomidementioning

confidence: 99%

Advances in antiangiogenic treatment of small-cell lung cancer

Lu¹,

Jiang²

2017

OTT

View full text Add to dashboard Cite

Small-cell lung cancer (SCLC), a poorly differentiated neuroendocrine malignancy, has a rapid growth rate, strong aggressiveness, early metastases, and poor prognosis. Angiogenesis greatly contributes to the metastatic process of SCLC, which has a higher vascularization compared with non-small-cell lung cancer (NSCLC). SCLC might constitute an ideal malignancy for assessing new antiangiogenic drugs and therapeutic strategies. Combining bevacizumab with paclitaxel has therapeutic benefits in chemoresistant, relapsed SCLC. The cisplatin–etoposide and bevacizumab combination, as the first-line treatment for extensive-stage SCLC, can improve progression-free survival (PFS), with an acceptable toxicity profile. Ziv-aflibercept combined with topotecan is promising for platinum-refractory SCLC. Chemotherapy combined with thalidomide cannot prolong survival. Maintenance sunitinib of 37.5 mg/day in extensive-stage SCLC patients following induction chemotherapy with platinum/etoposide improves median PFS by 1.6 months. Serum angiopoietin-2 concentrations and vascular endothelial growth factor levels correlate with poor prognosis. Bevacizumab, ziv-aflibercept, and sunitinib are worthy of further evaluation. Thalidomide, sorafenib, pomalidomide, and cediranib may not be suitable for SCLC.

show abstract

Selection of extreme phenotypes: the role of clinical observation in translational research

et al. 2010

View full text Add to dashboard Cite

Systematic collection of phenotypes and their correlation with molecular data has been proposed as a useful method to advance in the study of disease. Although some databases for animal species are being developed, progress in humans is slow, probably due to the multifactorial origin of many human diseases and to the intricacy of accurately classifying phenotypes, among other factors. An alternative approach has been to identify and to study individuals or families with very characteristic, clinically relevant phenotypes. This strategy has shown increased effi ciency to identify the molecular features underlying such phenotypes. While on most occasions the subjects selected for these studies presented harmful phenotypes, a few studies have been performed in individuals with very favourable phenotypes. The consistent results achieved suggest that it seems logical to further develop this strategy as a methodology to study human disease, including cancer. The identifi cation and the study with high-throughput techniques of individuals showing a markedly decreased risk of developing cancer or of cancer patients presenting either an unusually favourable prognosis or striking responses following a specifi c treatment, might be promising ways to maximize the yield of this approach and to reveal the molecular causes that explain those phenotypes and thus highlight useful therapeutic targets. This manuscript reviews the current status of selection of extreme phenotypes in cancer research and provides directions for future development of this methodology.

show abstract

Untitled

Cited by 7 publications

References 11 publications

Angiogenesis Inhibitors in Small Cell Lung Cancer

Angiogenesis Inhibitors in Small Cell Lung Cancer

Advances in antiangiogenic treatment of small-cell lung cancer

Selection of extreme phenotypes: the role of clinical observation in translational research

Contact Info

Product

Resources

About